The Global Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 2,287.2 Million in 2022 and is projected to exhibit a CAGR of 2.2% over the forecast period (2022– 2030).
Eli Lilly and Company is dedicated to expand the indication of Alimta (Pemetrexed), such expansion of indication is expected to support global pemetrexed market growth. For instance, in June 2018, Eli Lilly and Company, a pharmaceutical company, announced that ALIMTA (pemetrexed for injection) received US FDA (Food and Drug Administration) approval for an additional indication for the combination with carboplatin plus pembrolizumab as first-line treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), irrespective of PD-L1 expression status. The approval was based on tumor response rate and progression-free survival.
Moreover, on March 24, 2022, Eli Lilly and Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the Biologics License Application (BLA) for the investigational medicine sintilimab injection, PD-1 inhibitor in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC). Sintilimab is being developed by Innovent Biologics, Inc., a biopharmaceutical company and Lilly. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.
Global Pemetrexed Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus or COVID-19 outbreak started in Wuhan, China in 2019 and has spread across all the continents of the world, affecting various industries globally. The economy in countries all over the world such as India, Italy, Bangladesh, Sri Lanka, the U.S., Morocco, and others has been disrupted due to lockdowns implemented by governments to combat the spread of coronavirus since 2020.
Increasing number of appointment cancellation and postponement during the pandemic hindered the market growth of pemetrexe globally. For instance, in January 2022, BMC, part of Springer nature, an online research journal published a report which reported that, respiration therapy and physical therapy were unavailable for 57% to 70% of patients during the pandemic in Germany. Appointments for tumor-directed therapy, tumor imaging, and follow-up care were postponed or cancelled for 18.9%, 13.6%, and 14.8% of patients, respectively in Germany.
Thus, impact of the Coronavirus (COVID-19) pandemic hindered the growth of global pemetrexed market during the forecast period.
Global Pemetrexed Market: Key Developments
Increasing approval from the U.S. FDA (Food and Drug Administration) for the treatment of Nonsquamous Non-Small Cell Lung Cancer. For instance, in May 2021, Innovent Biologics, Inc., a biotechnology company and Eli Lilly and Company, a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for sintilimab injection in combination with pemetrexed and platinum chemotherapy for the first-line treatment of people with nonsquamous non-small cell lung cancer (NSCLC).
Increasing Launch of pemetrexed for injection by the key market player drives the global pemetrexed market growth for the forecast period. For instance, on May 27, 2022, Dr. Reddy’s Laboratories Ltd., a multinational pharmaceutical company, along with its subsidiaries together referred to as ‘Dr. Reddy’s’, announced the launch of Pemetrexed for Injection, 100 mg and 500 mg Single-Dose Vials, the generic equivalent of ALIMTA (pemetrexed for injection) in the U.S. market approved by the U.S. Food and Drug Administration (USFDA).
Browse 25 Market Data Tables and 20 Figures spread through 130 Pages and in-depth TOC on Global Pemetrexed Market, by Strength (100 mg and 500 mg), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies),and by Region - Global Forecast to 2030”
To know the latest trends and insights prevalent in the Pemetrexed Market, click the link below:
https://www.coherentmarketinsights.com/market-insight/pemetrexed-market-2458
Alimta is a patented drug of Eli Lilly and Company, hence Eli Lilly and Company is delicately working to prevent the launch of generic version of Alimta in key region such as U.S. from where Alimta generates about 50% of its revenue. For instance, in June 2018, Eli Lilly and Company got a favorable result from the U.S. District Court and prevented Hospira Inc. and India’s Dr. Reddy’s Laboratories from launching generic version of Alimta until the patent expires in 2022.
Key Takeaways of the Global Pemetrexed Market:
- Global pemetrexed market is expected to witness a CAGR of 2.2% during the forecast period, owing approval and launch of affordable generic of pemetrexed in the market, which is expected to increase its adoption.
- Among distribution channel, hospital pharmacies segment is expected to hold dominant position over the forecast period as reimbursement and pricing of drugs are more favorable in hospital pharmacies, owing to 340B pricing program ( Public Health Service Act requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to health care organizations that care for many uninsured and low-income patients)
- North America is expected to account for major market share in global pemetrexed market, owing to high prevalence of non-small cell lung cancer and its high treatment rate. Eli Lilly and Company, the patent holder of Alimta prevents the launch of generic version of Alimta in key regions to hold major share in market.
- Key players operating in the global pemetrexed market include, Eli Lilly and Company, Stada Arzneimittel AG, Eagle Pharmaceuticals, Inc, Fresenius Kabi USA, Teva Pharmaceuticals USA, Inc, Biocon, Pfizer Inc., Apotex Inc, Dr. Reddy’s Laboratories Ltd, Cadila Pharmaceuticals., Accord Healthcare, Accure Labs Pvt. Ltd, Shanghai Henlius Biotech, Inc., Janssen Global Services, LLC, and Checkpoint Therapeutics, Inc.
